Eutropics was founded on the belief that understanding and addressing the unique tumor biology of each patient will transform cancer care. We are developing a predictive, rapid, and scalable diagnostic platform designed to guide treatment decisions for both blood cancers and solid tumors. Our proprietary PRIMAB™-DX technology directly measures critical protein–protein interactions that determine how a cancer cell responds to therapy, rather than relying on static genomic markers alone. By revealing these functional response signals, PRIMAB™-DX closes major gaps in precision medicine and helps clinicians move patients more quickly to the therapies most likely to work for them.